Literature DB >> 11511720

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

E Kapaki1, K Kilidireas, G P Paraskevas, M Michalopoulou, E Patsouris.   

Abstract

The aim was to quantify tau protein and beta-amyloid (Abeta42) in the CSF of patients with sporadic Creutzfeldt-Jakob disease (CJD), Alzheimer's disease (AD), and controls. Double sandwich enzyme linked immunosorbent assays (ELISAs) were used for measurements. Tau was increased 58-fold in CJD and 3.5-fold in AD compared with controls, whereas Abeta42 was decreased 0.5-fold in both CJD and AD. A cut off level for tau protein at 2131 pg/ml successfully discriminated CJD from AD (100% specificity and 93% sensitivity). Tau protein concentration in CSF is probably an additional useful marker in differentiating CJD from AD.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11511720      PMCID： PMC1737566          DOI： 10.1136/jnnp.71.3.401

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  33 in total

1.  Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease.

Authors:  Ming-Jang Chiu; Ya-Fang Chen; Ta-Fu Chen; Shieh-Yueh Yang; Fan-Pei Gloria Yang; Tien-Wen Tseng; Jen-Jie Chieh; Jia-Chun Rare Chen; Kai-Yuan Tzen; Mau-Sun Hua; Herng-Er Horng
Journal:  Hum Brain Mapp       Date:  2013-10-15       Impact factor: 5.038

Review 2.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

3.  Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease.

Authors:  Moeko Noguchi-Shinohara; Tsuyoshi Hamaguchi; Ichiro Nozaki; Kenji Sakai; Masahito Yamada
Journal:  J Neurol       Date:  2011-03-01       Impact factor: 4.849

4.  CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt-Jakob disease suspected cases with inconclusive 14-3-3 result.

Authors:  M J Leitão; I Baldeiras; M R Almeida; M H Ribeiro; A C Santos; M Ribeiro; J Tomás; S Rocha; I Santana; C R Oliveira
Journal:  J Neurol       Date:  2016-06-29       Impact factor: 4.849

5.  Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?

Authors:  Pierre-Antoine Peyron; Christophe Hirtz; Eric Baccino; Nelly Ginestet; Laurent Tiers; Alex Yahiaoui Martinez; Sylvain Lehmann; Constance Delaby
Journal:  Int J Legal Med       Date:  2021-03-19       Impact factor: 2.686

6.  Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: over 10-Year Period Review.

Authors:  Silvia Koscova; Dana Zakova Slivarichova; Ivana Tomeckova; Katarina Melicherova; Martin Stelzer; Alzbeta Janakova; Dana Kosorinova; Girma Belay; Eva Mitrova
Journal:  Mol Neurobiol       Date:  2016-09-24       Impact factor: 5.590

7.  A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease.

Authors:  B Van Everbroeck; S Quoilin; J Boons; J J Martin; P Cras
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 8.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

9.  Unusual features of Creutzfeldt-Jakob disease followed-up in a memory clinic.

Authors:  Agnès Jacquin; Vincent Deramecourt; Serge Bakchine; Claude-Alain Maurage; Florence Pasquier
Journal:  J Neurol       Date:  2014-01-30       Impact factor: 4.849

Review 10.  [Neurobiological early diagnosis of Alzheimer's disease].

Authors:  H Hampel; S J Teipel; K Bürger
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.